Linda Baumann Comments on EpiPen’s Medicaid Rebate Status
Republicans from the Senate Finance Committee and House Energy and Commerce Commitee issued two letters this month to the Health and Human Services Office of Inspector General (HHS OIG) to review EpiPen’s status within the Medicaid drug rebate program.
They were also tasked with determining whether the allergy injection medication has been wrongly classified as a generic drug, which resulted in lower rebate payments from Mylan, the drug’s manufacturer. In the article “Senate Republicans Seek Review of EpiPen’s Medicaid Rebate Status” by Bloomberg BNA Health Care Daily Report, Arent Fox Health Care partner Linda Baumann noted that this is a serious problem for the Centers for Medicare & Medicaid Services when two Congressional committees raise concerns about agency activities. She also noted that these efforts are consistent with concerns that have been heavily publicized over the past few weeks regarding the price increases for prescription drugs, particularly EpiPen.
Click here to read the full article.
- Related Industries